PDCD1 and melanoma: Despite significantly improved outcomes with anti-CTLA-4 and anti-PD-1/PD-L1 therapies, approximately half of patients with advanced melanoma do not achieve a durable response and face a high risk of recurrence, for which treatment options are limited.